Abstracts Archive - Page 384 of 2607 - ACR Meeting Abstracts

Abstract Number: 1315 • ACR Convergence 2023
Elevated Serum Adiponectin Levels During Olokizumab Treatment in Patients with Rheumatoid Arthritis Correlate with High-density Lipoprotein Lipid Profile Independently of Body Mass Index: Results from the Double-blind, Randomized Controlled Phase III Studies
Elena Zonova¹, Antonio Abbate², Eugen Feist³, Sergey Yakushin⁴, Maria Lemak⁵, Alina Egorova⁵, Daria Bukhanova⁵, Sergey Grishin⁵, Sofia Kuzkina⁵, Mikhail Samsonov⁶ and EVGENY NASONOV⁷, ¹Novosibirsk State Medical University, Novosibirsk, Russia, ²Robert M. Berne Cardiovascular Research Center, Charlottesville, VA, ³Helios Department of Rheumatology and Clinical Immunology, Vogelsang-Gommern, Germany, ⁴Ryazan State Medical University, Ryazan, Russia, ⁵R-Pharm, Moscow, Russia, ⁶RPharm, Moscow, Russia, ⁷Scientific Research Institute of Rheumatology, Moscow, Russia
Background/Purpose: Active rheumatoid arthritis (RA) is associated with a higher prevalence of insulin resistance (IR). Dysregulation of adipokines driven by low-level systemic inflammation plays a…
Abstract Number: 1321 • ACR Convergence 2023
Effect of Subcutaneous Local Anaesthesia Prior to Intra-Articular Injection: An Open Label, Paired-group, Randomized Controlled Trial
Alan Shaji¹, Varun Dhir², Chandra Bhushan Prasad³, Shankar Naidu¹, Aman Sharma⁴, Shefali Sharma⁵, Babita Ghai¹ and Sanjay Jain¹, ¹PGIMER, Chandigarh, India, ²PGIMER, CHD, INDIA, Chandigarh, India, ³Healthway Hospital, Goa, Zuarinagar, India, ⁴PGIMER, Chandigarh, India, Chandigarh, India, ⁵PGIMER< Chandigarh, Chandigarh, India
Background/Purpose: Intraarticular injections are commonly used both for diagnostic and therapeutic injections of glucocorticoids in patients with inflammatory arthritis. The procedural pain felt by patients…
Abstract Number: 1319 • ACR Convergence 2023
Real World Data on Antifibrotics in Rheumatoid Arthritis-Interstitial Lung Disease. National Multicenter Study of 73 Patients
Belén Atienza-Mateo¹, Ana Serrano-Combarro², Maria Martin-Lopez³, Santos Castañeda⁴, Rafael Benito Melero-Gonzalez⁵, Jesus Loarce-Martos⁶, Natalia Mena Vazquez⁷, Carmen carrasco-Cubero⁸, Carolina Diez-Morrondo⁹, David Castro-Corredor¹⁰, Tomás Vazquez-Rodriguez¹¹, andrea Garcia-Valle¹², Gema Bonilla¹³, Marina Rodriguez-lopez¹⁴, Ignacio Brana Abascal¹⁵, SARA MARIA ROJAS HERRERA¹⁶, Juan Camilo Sarmiento-Monroy¹⁷, Pablo Andujar-Brazal¹⁸, Juan Ramon De Dios¹⁹, Carmen Gonzalez-Montagut Gomez²⁰, Sergio Ordonez-Palau²¹, Anahy Maria Brandy-Garcia²², Fernando Lozano²³, Maria Lopez-Lasanta²⁴, Cristina Campos Fernández²⁵, Marta Garijo Bufort²⁶, Ivette Casafont-Sole²⁷, Calderon Goercke²⁸, Carlota Laura Iñiguez²⁹, Francisco Ortiz-Sanjuán³⁰, Emilio Giner-Serret³¹, Bryan Josue Flores Robles³², Mireia Moreno³³, Evelin Cecilia Cervantes-Perez³⁴, Diego Ferrer³⁵, Ricardo Blanco³⁶ and On behalf of the Collaborative Group Members³⁷, ¹Rheumatology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ²Division of Rheumatology, Hospital Universitario Marqués de Valdecilla. IDIVAL, Immunopathology group, Santander, Spain, ³Hospital 12 de Octubre, Madrid, Spain, ⁴Hospital Universitario de la Princesa, Madrid, Spain, ⁵CHU Vigo, O Carballino, Spain, ⁶Ramón y Cajal University Hospital, Madrid, Spain, ⁷IBIMA, Málaga, Spain, ⁸Department of Rheumatology, Hospital Universitario de Badajoz, Badajoz, Spain, ⁹Division of Rheumatology, Hospital de León, León, Spain, ¹⁰General University Hospital of Ciudad Real, Santa Cruz de Mudela (Ciudad Real), Spain, ¹¹Rheumatology, Complejo Hospitalario Universitario de Ferrol, A Coruña, Spain, ¹²Division of Rheumatology, Complejo Asistencial Universitario de Palencia, Palencia, Spain, ¹³Department of Rheumatology, Hospital Clínico Universitario La Paz, Madrid, Spain, ¹⁴Division of Rheumatology, Hospital Clínico Universitario de Santiago, La Coruna, Spain, ¹⁵Division of Rheumatology, Hospital Universitario Central de Asturias, Oviedo, Spain, ¹⁶Division of Rheumatology, Hospital de Mérida, Mérida, Spain, ¹⁷Hospital Clínic, Barcelona, Spain, ¹⁸Division of Rheumatology, Hospital Universitario Doctor Peset, Valencia, Spain, ¹⁹Hospital Universitario Araba, Vitoria, Spain, ²⁰H. Clínico Universitario de Valladolid, Valladolid, Spain, ²¹H. Arnau de Vilanova, Lleida, Spain, ²²Hospital Germans Trias i Pujol, Badalona, Spain, ²³Hospital Universitario 12 de Octubre, Madrid, Spain, ²⁴Hospital Universitari Vall d'Hebron, Rheumatology, Barcelona, Spain, ²⁵Hospital General Universitario Valencia, Valencia, Spain, ²⁶H. de Sagunto, Valencia, Italy, ²⁷Hospital Universitari Germans Trias i Pujol, Badalona, Spain, ²⁸Hospital Universitario Marqués de Valdecilla, Santander, Spain, ²⁹Hospital Universitario Lucus Augusti, Lugo, Spain, ³⁰Hospital Universitario y Politécnico La Fe, Valencia, Spain, ³¹Hospital Royo Villanova, Teruel, Spain, ³²Hospital Universitario San Pedro, Logroño, Spain, ³³Parc Tauli Hospital Universitari, I3PT(UAB), Barcelona, Spain, ³⁴Complexo Hospitalario Universitario de Pontevedra, Pontevedra, Spain, ³⁵Division of Pneumology, Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁶Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain, ³⁷Spanish Collaborative Group of Interstitial Lung Disease Associated with Rheumatoid Arthritis, Spain, Spain
Background/Purpose: Interstitial lung disease (ILD) is a critical complication of rheumatoid arthritis (RA). Abatacept and rituximab are the preferred disease-modifying antirheumatic drugs (DMARDs) for RA-ILD.…
Abstract Number: 1287 • ACR Convergence 2023
Impact of Body Mass Index (BMI) on Rheumatoid Arthritis Disease Activity and Musculoskeletal Ultrasound Measures
Nicolette Morris¹, Elena Saab², Lucia Chen¹, Jenny Brook¹, Gurjit S Kaeley³, David Elashoff¹ and Veena Ranganath¹, ¹David Geffen School of Medicine, UCLA, Los Angeles, CA, ²Wake Forest University School of Medicine, Los Angeles, CA, ³University of Florida College of Medicine – Jacksonville, Ponte Vedra Beach, FL
Background/Purpose: Rheumatoid arthritis (RA) patients with obesity are less likely to respond to therapy and achieve remission. Obesity is a known driver of inflammatory processes…
Abstract Number: 1309 • ACR Convergence 2023
Refractory RA Patients for Targeted Therapies in Real Life
Elena Grau Garcia¹, Laura Mas Sanchez², Pablo Francisco Muñoz Martínez³, Carmen Riesco Barcena¹, Alba Maria Torrat Noves¹, Daniel Ramos Castro¹, Anderson Victor Huaylla Quispe¹, Iago Alcantara Alvarez¹, Belen Villanueva Mañez¹, Ernesto Tovar Sugrañes¹, Elvira Vicens Bernabeu¹, Hikmat Charia¹, Marta De la Rubia Navarro², Luis Gonzalez Puig¹, Jose Ivorra Cortes¹, Samuel Leal Rodriguez¹, Isabel Martinez Cordellat¹, Rosa Negueroles Albuixech¹, Jose Eloy Oller Rodriguez¹, Ines Canovas Olmos¹, Carmen Najera Herranz¹ and Jose Andres Roman Ivorra⁴, ¹Rheumatology Department. HUP La Fe, Valencia, Spain, ²Rheumatology Department. HUP La Fe, Valéncia, Spain, ³Rheumatology Department. HUP La Fe, Sagunto, Spain, ⁴Hospital Universitari i Politècnic la Fe, Valencia, Spain
Background/Purpose: Despite the increasing number of available targeted therapies (TT) in rheumatoid arthritis (RA), a proportion of RA patients fail to respond to their first…
Abstract Number: 1330 • ACR Convergence 2023
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial
John Lampa¹, Dan Nordstrom², Ronald van Vollenhoven³, Merete Hetland⁴, Espen A Haavardsholm⁵, Mikkel Østergaard⁶, Anna Rudin⁷, Marte Schrumpf Heiberg⁵, Michael Nurmohamed³, Bjorn Gudbjornsson⁸, Kristina Lend⁹, Kim Hørslev-Petersen¹⁰, Tuulikki Sokka-Isler¹¹, Gerdur Maria Grondal¹², Simon Krabbe¹³, Joakim Lindqvist¹⁴, Anna-Karin Hultgård Ekwall¹⁵, Daniel Glinatsi¹⁶, Meliha Kapetanovic¹⁷, Cidem Gentline¹⁴, Anna-Birgitte Aga¹⁸, Heikki Relas², Tove Lorenzen¹⁹, Giovanni Cagnotto²⁰, Johan Back²¹, Oliver Hendricks²², Bas Dijkshoorn²³, Kajsa Öberg²⁴, Maud-Kristine Aga Ljoså²⁵, Eli Brodin²⁶, Hanne Merete Lindegaard²⁷, Annika Söderbergh²⁸, Milad Rizk²⁹, Alf Kastbom³⁰, Per Larsson³¹, Line Uhrenholt³², Søren Just³³, David J Stevens³⁴, Trine B Laurberg³⁵, Gunnstein Bakland³⁶, Inge Olsen³⁷, Joseph Sexton¹⁸ and Till Uhlig¹⁸, ¹Stockholm County, Hãsselby, Sweden, ²Helsinki University Hospital, Helsinki, Finland, ³Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁴Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Denmark, ⁵Diakonhjemmet Hospital, Oslo, Norway, ⁶Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Centre for Head and Orthopaedics, Rigshospitalet; University of Copenhagen, Copenhagen, Denmark, ⁷Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden, ⁸Centre for Rheumatology Research, University Hospital, Reykjavik, Iceland, ⁹Amsterdam UMC, Karolinska Institute, Stockholm, Sweden, ¹⁰University of Southern Denmark, Odense, Denmark, ¹¹Jyvaskyla Central Hospital, Jyväskylä, Finland, ¹²Department for Rheumatology, Landspitali University Hospital, Reykjavik, Iceland, ¹³Herlev-Gentofte University Hospital, Herlev, Denmark, ¹⁴Karolinska University Hospital, Stockholm, Sweden, ¹⁵Department of Rheumatology and Inflammation research, Sahlgrenska Academy, University of Gothenburg, Kullavik, Sweden, ¹⁶Copenhagen Center for Arthritis Research, Rigshospitalet, Copenhagen, Sweden, ¹⁷Lund University and Skåne University Hospital, Lund, Sweden, ¹⁸Center for Treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway, ¹⁹Silkeborg University Hospital, Silkeborg, Denmark, ²⁰Skåne University Hospital, Lund, Sweden, ²¹Uppsala University Hospital, Uppsala, Sweden, ²²Danish Hospital for Rheumatic Diseases, Sønderborg, Denmark, ²³Amsterdam Rheumatology and Immunology Center, Location Reade, Amsterdam, Netherlands, ²⁴Falu Hospital, Falun, Sweden, ²⁵Ålesund Hospital, Ålesund, Norway, ²⁶Haukeland University Hospital, Bergen, Norway, ²⁷Odense Hospital, Odense, Denmark, ²⁸Örebro University Hospital, Örebro, Sweden, ²⁹Västmanlands Hospital Västerås, Västerås, Sweden, ³⁰Linköping University, Linköping, Sweden, ³¹Academic Specialist Center, Stockholm, Sweden, ³²Aalborg University Hospital, Aalborg, Denmark, ³³Section of Rheumatology, Department of Medicine, Odense University Hospital – Svendborg Hospital, Odense, Denmark, ³⁴St. Olavs Hospital, Trondheim, Norway, ³⁵Aarhus University Hospital, Aarhus, Denmark, ³⁶University Hospital of North Norway, Tromsø, Norway, ³⁷Oslo University Hospital, Oslo, Norway
Background/Purpose: The optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established. Methods: In this investigator-initiated, randomized, open-label study (NCT01491815), patients with…
Abstract Number: 1312 • ACR Convergence 2023
Uncovering Risk Factors for Adverse Events and Infections in Rheumatoid Arthritis and Rheumatoid Arthritis with Interstitial Lung Disease Under Biologics or Targeted Synthetic DMARDs: Insights from the KOBIO Registry
Ji-Won Kim¹, Ju-Yang Jung¹, Chang-Hee Suh² and Hyoun-Ah Kim¹, ¹Ajou University School of Medicine, Suwon, South Korea, ²Ajou University Hospital, Suwon, South Korea
Background/Purpose: This study aimed to identify risk factors associated with adverse events (AEs) and infections in patients with rheumatoid arthritis (RA) and comorbid interstitial lung…
Abstract Number: 1323 • ACR Convergence 2023
Distinct Treatment Responses in Patients with Rheumatoid Arthritis Receiving Filgotinib 200 Mg over 12 Months: A Post Hoc Analysis of FINCH 1
Peter C. Taylor¹, Yoshiya Tanaka², Emily Aiello³, Thomas P.A. Debray⁴, Chris Watson⁵, Kristina Harris⁶ and Gerd Burmester⁷, ¹Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, ²University of Occupational and Environmental Health, Kitakyushu, Japan, ³Real-world Analytics, Cytel, Toronto, ON, Canada, ⁴Biostatistics, Galapagos NV, Mechelen, Belgium, ⁵Medical Affairs, Galapagos Biotech Ltd., Cambridge, United Kingdom, ⁶Medical Safety, Galapagos NV, Mechelen, Belgium, ⁷Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany
Background/Purpose: FINCH 1 (NCT02889796) was a Phase 3 randomized controlled trial evaluating filgotinib (FIL) in patients with rheumatoid arthritis and an inadequate response to methotrexate…
Abstract Number: 1327 • ACR Convergence 2023
Effects of Long-Term Low Dose Glucocorticoid Treatment for Rheumatoid Arthritis on Body Weight and Blood Pressure: A Pooled Analysis of Individual Patient Data from Five Randomised Trials
Andriko Palmowski¹, Sabrina Mai Nielsen², Zhivana Boyadzhieva³, Linda Hartman⁴, Judith Oldenkott⁵, Björn Svensson⁶, Ingiäld Hafström⁷, Siegfried Wassenberg⁸, Ernest Choy⁹, John Kirwan¹⁰, Robin Christensen¹¹, Maarten Boers¹² and Frank Buttgereit¹³, ¹Charité - Universitätsmedizin Berlin, Berlin, Germany, ²The Parker Institute, Bispebjerg and Frederiksberg Hospital, Copenhagen, Denmark, ³Charité Universitatsmedizine - Berlin, Berlin, Germany, ⁴Amsterdam University Medical Centers, Amsterdam, Netherlands, ⁵Charite - University Medicine Berlin, Berlin, Germany, ⁶Lund University, Lund, Sweden, ⁷Karolinska Institutet, Stockholm, Sweden, ⁸Rheumazentrum Ratingen, Ratingen, Germany, ⁹Section of Rheumatology, Cardiff University, Cardiff, United Kingdom, ¹⁰University of Bristol, Bristol, United Kingdom, ¹¹Musculoskeletal Statistics Unit, The Parker Institute, Copenhagen, Denmark, ¹²Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, ¹³Charité Universitätsmedizin, Dept. Rheumatology, Berlin, Germany
Background/Purpose: High-dose glucocorticoids (GCs) can cause weight gain and hypertension. It is unclear whether GCs at ≤7.5mg/day prednisone equivalent ("low dose"), administered for rheumatoid arthritis…
Abstract Number: 1332 • ACR Convergence 2023
Patient-Reported Outcomes, Disease Activity and Safety in 798 Patients with RA Treated with Filgotinib: Up to 1-Year Interim Results from a Prospective Observational Study (FILOSOPHY)
Gerd Burmester¹, Patrick Verschueren², Jerome AVOUAC³, Roberto F. Caporali⁴, Karen Bevers⁵, Neil Betteridge⁶, Thomas P.A. Debray⁷, Francesco De Leonardis⁸, Susana Romero Yuste⁹, Monia Zignani⁸ and James Galloway¹⁰, ¹Charité – Universitätsmedizin Berlin, Department of Rheumatology and Clinical Immunology, Berlin, Germany, ²Department of Rheumatology, University Hospital Leuven and KU Leuven, Leuven, Belgium, ³Rheumatology A Department, Hôpital Cochin, AP-HP Centre - Université Paris Cité, Paris, France, ⁴Department of Clinical Sciences and Community Health, University of Milan, and Department of Rheumatology and Medical Sciences, ASST Gaetano Pini-CTO, Milano, Italy, ⁵Department of Rheumatology, Sint Maartenskliniek, Nijmegen, Netherlands, ⁶Neil Betteridge Associates, London, United Kingdom, ⁷Biostatistics, Galapagos NV, Mechelen, Belgium, ⁸Medical Affairs, Galapagos GmbH, Basel, Switzerland, ⁹Complexo Hospitalario Universitario, Pontevedra, Spain, ¹⁰King's College London, London, United Kingdom
Background/Purpose: The efficacy of filgotinib (FIL) for treating RA has been demonstrated in clinical trials. Real-world data are valuable to assess patient-reported outcomes such as…
Abstract Number: 1216 • ACR Convergence 2023
“I Call It Zombie Hands and Feet, That’s Actually How I Found out I Had This Disease”: Disease Symptoms and Treatment Side Effects in a Diverse Sample of Patients with Early Limited Cutaneous and Diffuse Cutaneous Systemic Sclerosis
Chelsea Perschon¹, Emilie Jaeger¹, George Greene¹, Alain Lescoat², Yen Chen³, Susan Murphy³, Sara Shaunfield¹, David Cella¹ and Dinesh Khanna³, ¹Northwestern University Feinberg School of Medicine, Chicago, IL, ²University Rennes, Rennes, France, ³University of Michigan, Ann Arbor, MI
Background/Purpose: Systemic sclerosis (SSc) is a multisystem autoimmune rheumatic disease with heterogeneous manifestations, including common symptoms such as pain, fatigue, dyspnea, and Raynaud's phenomenon. It…
Abstract Number: 1311 • ACR Convergence 2023
T Cell Subset Signatures Predicted Clinical Response to Etanercept-biosimilar Yisaipu in Patients with Rheumatoid Arthritis
Huaqun Zhu¹, Sumei Tang¹, Gong Cheng¹, Yingni Li¹, Yun Li¹, Feng Sun¹, Xiaolin Sun¹, Jiahui Cheng¹, Ru Li¹ and Zhanguo Li², ¹Peking University People’s Hospital, Beijing, China, ²Peking University Health Science Center, Department of Rheumatology and Immunology, People's Hospital, Beijing, China
Background/Purpose: Our study aimed to use machine-learning approaches to characterize the immune cell profiles of patients who were inadequate responders to Etanercept-Biosimilar Yisaipu (Yisaipu-IRs) and…
Abstract Number: 1277 • ACR Convergence 2023
Relationship Between Quality of Life and the Region of the Affected Joints in Japanese Patients with Rheumatoid Arthritis: A Cross-sectional Study
Kenichiro Tokunaga¹, Takahiro Nishino², Hideto Oshikawa¹, Toshihiro Matsui³ and Shigeto Tohma⁴, ¹Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²National Hospital Organization Sagamihara National Hospital, Kanagawa, Japan, ³NHO Sagamihara National Hospital, Kanagawa, Japan, ⁴NHO Tokyo National Hospital, Dallas, TX
Background/Purpose: This clinical study aimed to investigate the relationship between affected joints and the quality of life (QOL) in patients with rheumatoid arthritis (RA) in…
Abstract Number: 1316 • ACR Convergence 2023
Influence of Rheumatoid Factor on Serum Drug Levels of TNF Inhibitors with Different Structures in Rheumatoid Arthritis
Ana Martinez Feito¹, Chamaida Plasencia-Rodríguez², Marta Novella-Navarro², Johanna E. Gehin³, Borja Hernandez-Breijo⁴, Claudia M.Brenis⁵, Alejandro Villalba⁶, Elisa Fernandez-Fernandez⁴, Irene Monjo⁷, Dora Pascual-Salcedo⁸, Pilar Nozal⁹ and Alejandro Balsa², ¹Immuno-Rheumatology research group , Institute for Health Research (IdiPAZ), Madrid, Spain, ²Hospital Universitario La Paz, Madrid, Spain, ³Dept. of Medical Biochemistry, Oslo University Hospital, Oslo, Norway, ⁴La Paz University Hospital, Madrid, Spain, ⁵VIB-UGent Inflammation Research Center Gent, Belgium, Gent, Belgium, ⁶Rheumatology Department, La Paz University Hospital, Madrid, Spain, ⁷University Hospital La Paz, Madrid, Spain, ⁸Immuno-Rheumatology Research Group, La Paz University Hospital, Madrid, Spain, ⁹Immunology Unit in La Paz University Hospital-Idipaz, Madrid, Spain
Background/Purpose: Elevated rheumatoid factor (RF) in patients with rheumatoid arthritis (RA) is associated with higher disease activity. A significantly lower efficacy of TNF inhibitors (TNFi)…
Abstract Number: 1234 • ACR Convergence 2023
Cognitive Performance Score of the Pediatric Automated Neuropsychological Assessment Metrics Software in a Brazilian Cohort and Its Association with Disease Activity
Jaqueline de amorim¹, Simone Kishimoto¹, Paula Fernandes¹, Roberto Marini², Zahi Touma³, Hermine Brunner⁴ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil, ²Revista Brasileira de Reumatologia, Campinas, Brazil, ³University of Toronto, Toronto, ON, Canada, ⁴Cincinnati Children's Hospital Medical Center, Division of Rheumatology, Cincinnati, OH
Background/Purpose: The PedAnam (Pediatric Automated Neuropsychological Assessment Metrics) is an automatic software to evaluate cognitive performance that has recently been validated into Portugues (Brazil). The…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].